Home / Market News / $ARAY
benzinga Corporate Catalyst Impact 75/100 ● positive

Accuray shares are trading higher after the company announced t had entered into agreements with Samsung HME America to pursue advanced volumetric imaging capabilities for the CyberKnife System

Sep 28, 2026, 12:53 PM UTC · Primary ticker $ARAY

Accuray shares are up significantly due to a strategic partnership with Samsung HME America, indicating potential for enhanced product offerings and market share. This collaboration could lead to technological advancements in cancer treatment, benefiting both companies involved.

This headline represents a significant corporate catalyst for Accuray. The partnership with Samsung HME America, a major player in medical technology, lends credibility and resources to Accuray's CyberKnife System. This collaboration could lead to advanced volumetric imaging capabilities, enhancing the system's efficacy and potentially expanding its market adoption. The medical devices sector, particularly in oncology, stands to benefit from such technological advancements. Trading implications suggest a positive outlook for ARAY, with potential for sustained growth as the partnership progresses and new capabilities are developed. Risks include the successful integration of technologies and market acceptance of the new features.

$ARAY positive Direct beneficiary of partnership
$SSNLF positive Partner in advanced imaging development
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.